Drug Trial Radar · NCT01564784
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Jan 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
326
Actual
Start
Aug 2, 2012
Primary completion
Mar 8, 2016
Study completion Jan 4, 2017
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- UCB Pharma
- First posted
- Mar 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.
Conditions
- Acute Lymphoblastic Leukemia
Interventions
inotuzumab ozogamicinDrug
Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
FLAG (fludarabine, cytarabine and G-CSF)Drug
Dose: cytarabine 2.0 g/m\^2/day IV days 1-6 fludarabine30 mg/m\^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
HIDAC (high dose cytarabine)Drug
cytarabine 3 g/m\^2 IV every 12 hours for up to 12 times
cytarabine and mitoxantroneDrug
mitoxantrone 12 mg/m\^2 IV days 1-3 cytarabine 200 mg/m\^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed by the Endpoint Adjudication Committee (EAC)Time frame: Screening, Day 16 to 28 of Cycles 1, 2 and 3, then every 1 to 2 cycles (or as clinically indicated) up to approximately 4 weeks (end of treatment [EoT]) from the last dose
- Overall Survival (OS)Time frame: Up to 5 years after randomization or 2 years from randomization of the last participant, whichever occurs first.
Locations
198 sites in 20 countries. Site status is shown where the registry gives one.
Investigational Drug Services - UC San Diego Moores Cancer Center
La Jolla, California
UC San Diego Medical Center - La Jolla
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
Children's Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles
Los Angeles, California
Keck Hospital of USC
Los Angeles, California
LAC+USC Medical Center
Los Angeles, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Drug Information/Investigation Drug
Los Angeles, California
UCLA Hematology/Oncology Clinic
Los Angeles, California
UCLA Ronald Reagan Medical Center
Los Angeles, California
UCLA Rrmc
Los Angeles, California
UC Irvine Medical Center
Orange, California
Children's Hospital of Orange County
Orange, California
UC Irvine Medical Center
Orange, California
Freidenrich Center for Translational Research (CTRU), Stanford University
Palo Alto, California
UC San Diego Medical Center - Hillcrest
San Diego, California
Martha Hamilton, Investigational Drug Services, Dept of Pharmacy
Stanford, California
Stanford Cancer Institute
Stanford, California
Stanford University Hospital and Clinics
Stanford, California
University of Colorado Cancer Center
Aurora, Colorado
University of Colorado Hospital, Cancer Center Infusion Center
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
Yale-New Haven Hospital & Smilow Cancer Center
New Haven, Connecticut
Miami Children's Hospital
Miami, Florida
MD Anderson Cancer Center Orlando - 5th Floor Investigational Pharmacy
Orlando, Florida
MD Anderson Cancer Center Orlando
Orlando, Florida
Orlando Heart Health Institute
Orlando, Florida
Orlando Regional Medical Center
Orlando, Florida
Emory University Hospital
Atlanta, Georgia
Investigational Drug Service, Emory University Clinic
Atlanta, Georgia
The Emory Clinic
Atlanta, Georgia
Winship Cancer Institute, Emory University
Atlanta, Georgia
Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia
Northside Hospital
Atlanta, Georgia
Georgia Regents Medical Center Pharmacy, Georgia Regents University Cancer Center
Augusta, Georgia
Georgia Regents University
Augusta, Georgia
Northwestern Medical Faculty Foundation
Chicago, Illinois
Northwestern Medicine Developmental Therapeutics Institute
Chicago, Illinois
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.